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564 Abstracts February 2014Board approval was obtained, patients were retrospectively and then pro-
spectively identiﬁed and followed up for a 2-year period.
Results: Sixty-three AAAVgs were reviewed. Patient were an average
age of 55 years (range, 23-85 years), and 93% had documented prior access.
Thirty-eight patients required graft interventions in the follow-up period.
Twenty-one balloon angioplasties were performed for outﬂow venous ste-
nosis. Fourteen grafts thrombosed at an average of 461 days after implant.
Seven patients had bacteremia resulting in four graft removals (6%) as the
infective source. Two wound complications (one hematoma, one superﬁcial
wound dehiscence) occurred, but the graft was preserved. Notably, no pa-
tient required treatment for steal. The average primary patency rate was 85%
at 30 days, 51% at 6 months, and 33% at 1 year. Primary assisted patency was
90% at 6 months, 79% at 1 year, and 37% at 2 years. Secondary patency was
92% at 6 months and 58% at 1 year. Twenty-one patients required a new
access at an average of 477 days after the initial placement. Since receiving
their grafts, 25 of the 63 patients have died, and one patient received a
transplant.
Conclusions: AAAVgs are appropriate for patients who have few up-
per extremity access options. The patency rates for this “bailout” procedure
are at least equivalent to other upper extremity AV grafts. The lack of symp-
tomatic steal is an important beneﬁt. The infection rate is lower than in
femoral grafts, and correspondingly, AAAVgs can even be considered for
primary use in patients that have disadvantaged upper extremity vasculature
or who are at increased risk of steal syndrome.
Patient Compliance Limits the Efforts of Quality Improvement
Initiatives on Arteriovenous Fistula Maturation
Susanna K. Lynch, BS, Sadaf S. Ahanchi, MD, David J. Dexter, MD, Marc
H. Glickman, MD, Jean M. Panneton, MD. Eastern Virginia Medical
School, Norfolk, Va
Objectives: Our institutional quality improvement (QI) initiative
monitors the schedule for arteriovenous ﬁstula (AVF) maturation with
follow-up #30 days after creation, ﬁstulogram #40 days if indicated, and
a second ofﬁce visit #8 weeks. Additionally, a patient liaison contacts pa-
tients and dialysis units in cases of delayed follow-up. The purpose of this
study is to determine the impact of the QI initiative on patient compliance
and overall time to AVF maturation.
Methods: We performed a retrospective review of patients undergo-
ing initial radiocephalic (RC), brachiocephalic (BC), and basilic vein trans-
position (BVT) creation before the QI initiative (pre-QI group: January to
April 2012) and during the QI period (QI group: January to April 2013).
Categoric data were compared using c2 analysis, and nominal data were
compared using the Student t-test.
Results: We reviewed 198 ﬁrst-time AVF creations in patients (57%
male) with a mean age of 61 years. Demographics and comorbidities be-
tween the pre-QI and QI groups were similar. During the pre-QI period,
110 initial AVFs were created: 28% RC, 44% BC, and 28% BVT, whereas
during the QI period, 88 initial AVFs were created: 27% RC, 51% BC,
and 22% BVT (c2 ¼ 0.487). Compliance with the 30-day postoperative
appointment increased signiﬁcantly after the QI initiative, from 48% in
the pre-QI group to 65% in the QI group (P ¼ .015). Yet, the QI initiative
did not maintain an impact on the subsequent follow-up checkpoints. No
statistical difference was identiﬁed for compliance with ﬁstulogram #40
days of access creation (pre-QI: 12% vs QI: 25%; P ¼ .093) and for compli-
ance with the 8-week postoperative appointment (pre-QI: 33% vs QI: 23%;
P ¼ .457). Both checkpoints demonstrated a very high noncompliance rate.
Accordingly, time to maturation was 88 days for both the pre-QI and QI
group, with a failure to mature rate of 22% for the pre-QI group and 21%
for the QI group.
Conclusions: The QI initiative signiﬁcantly increased the number of
patients complying with the ﬁrst 30-day follow-up appointment after access
creation. However, patient compliance with a timely ﬁstulogram and the
second follow-up appointment was very poor and not inﬂuenced by the
QI initiative, limiting the functional impact of the QI initiative on time to
AVF maturation.
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Objectives: The safety and efﬁcacy of vascular closure devices in the
arterial system has been well documented. However, there are no reports
describing the use of these devices in the venous system, despite the
increasing frequency of percutaneous venous interventions, often involving
large-bore sheaths in anticoagulated patients. This report describes our
experience using the Perclose ProGlide (Abbott Vascular Devices, Pleasan-
ton, Calif) suture-mediated device in venous closure.Methods: A retrospective review of all patients undergoing off-label
venous access closure with the Perclose was performed from 2008 to
2012. Seventy patients (50% male; mean age, 28 years) underwent 70
femoral venous access closures for sheaths ranging from 9F to 22F (mean,
18F). A single Perclose device was used postintervention for sheaths up to
12F, and two Perclose devices were used with the “Perclose” technique
for sheaths >12F. Indications for intervention included nonthrombotic
May-Thurner syndrome with leg swelling, May-Thurner syndrome with
deep vein thrombosis, and pulmonary insufﬁciency requiring a percutaneous
pulmonic valve. All patients underwent full anticoagulation intraprocedur-
ally (activated clotting time >250 seconds) and at the time of vessel access
closure. Mean follow-up was 13 months, and consisted of a physical exam-
ination (all patients) and venous duplex ultrasound imaging (20%). Main
outcome measures were deep venous thrombosis (DVT) and access site
hematoma.
Results: During longitudinal follow-up, there were no documented
cases of DVT or access site hematoma. Venous duplex ultrasound imaging
was performed between 1 and 56 months postprocedurally, with normal
ﬂow documented in all studied patients. Six patients (9%) had ipsilateral
leg swelling necessitating imaging that demonstrated no evidence of DVT
or venous stenosis. Two deaths occurred (one <30 days, one late) due to
heart failure in pulmonary insufﬁciency patients, but neither was procedur-
ally related.
Conclusions: The use of suture-mediated devices in the venous sys-
tem appears to be well tolerated, with no documented cases of DVT in
our series. The absence of any occurrences of hematoma in these patients,
despite large-bore sheath access and full anticoagulation, suggests a clinical
beneﬁt for use of suture-mediated closure devices. Prospective studies with
routine duplex imaging after Perclose use in the venous system will better
elucidate the long-term safety of this technique.
United States National Survey of Vascular Surgery Consent
Mark E. O’Donnell, MMedSc, MD, FRCS, Grant T. Fankhauser, MD,
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Samuel R. Money, MD. Mayo Clinic, Phoenix, Ariz
Objectives: Currently, there are no explicit guidelines for informed
consent for vascular surgical interventions. Unfortunately, there is evidence
to suggest that consent deﬁciencies occur. The objective of this survey was
to catalog current peer practice and collate consensus relating to vascular
surgery patient consent.
Methods: A prospective anonymous online survey was adminis-
tered using Survey Monkey to members of the Society for Clinical
Vascular Surgery in June 2013. After completion of provider demo-
graphic details, each member evaluated general and procedural-speciﬁc
complications for arterial and venous interventions that should be dis-
cussed with patients during the informed consent process. Greater
than 75% reporting for a speciﬁc complication was deemed the threshold
for consensus opinion.
Results: Of 1210 members, 179 (14.8%) completed the survey. The
majority of respondents were staff surgeons (85.5%), followed by vascular
fellows (11.2%). Both groups considered vascular fellows competent to
obtain consent. The majority of patients were consented primarily by the
staff surgeons (67.6%) #24 hours of surgery (43%). This was done in the
outpatient (67.4%) or preoperative holding areas (66%). A procedure-spe-
ciﬁc, preprinted consent form was used in 95% of patients, with additional
written documentation provided in 59.7%. General complications discussed
before arterial surgery included bleeding (94.9%), cardiac (94.9%), cerebro-
vascular (92.6%), wound infection (90.4%), respiratory (78.7%), and throm-
boembolic (76%) events. Although respondents provided consent consensus
for a number of core vascular procedures, in patients undergoing open
aortic surgery, 10.2%, 14.4%, and 13.6% reported no discussion of bleeding,
impotence, or lower limb ischemia, respectively. Endoleak (5.6%), follow-up
surveillance (14.0%), graft occlusion/lower limb ischemia (8.4%), and rein-
tervention possibilities (10.3%) were additionally not documented during
EVAR consent by survey respondents. Surprisingly, cranial nerve injury
and restenosis were not discussed by 6.5% and 18.7% of vascular surgeons
performing carotid endarterectomy. For patients undergoing limb bypass
procedures, graft occlusion, limb loss, edema, and procedural failure were
not discussed in 5% to 9.9% of cases. General complications described dur-
ing venous procedures included bruising (90%), bleeding (86%), thrombo-
embolic events (87%), and wound infections (81.8%). However, nerve
injury, failure to improve symptoms, scarring, and recurrence were omitted
from discussion by 17.7%, 11.5%, 22.2%, and 12.5%, of respondents. Only
37% and 5.8% of vascular centers provided informal and formal consent
training, respectively.
Conclusions: The informed consent process presently used by most
providers is nonstandardized and inadequate. Recognized complications
for procedures are frequently not discussed during the informed consent
